SGSamuel García-García

Samuel García-García

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Samuel García-García has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Alain Ocampo-Sosa

    Servicio de Microbiología, Hospital Universitario Marqués de Valdecilla-Instituto de Investigación Marqués de Valdecilla (IDIVAL), Spain

    2 shared publications
  • Jorge Calvo-Montes

    Servicio de Microbiología, Hospital Universitario Marqués de Valdecilla – IDIVAL

    2 shared publications
  • Jorge Rodríguez-Grande

    Servicio de Microbiología, Hospital Universitario Marqués de Valdecilla-Instituto de Investigación Marqués de Valdecilla (IDIVAL), Spain

    2 shared publications
  • Sergio García-Fernández

    Servicio de Microbiología, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain

    2 shared publications
  • Concha Ortiz-Cartagena

    Multidisciplinary and Translational Microbiology group (MicroTM), Biomedical Research Institute of A Coruña (INIBIC), Microbiology Service, University Hospital of A Coruña (CHUAC), University of A Coruña (UDC), A Coruña, Spain; Study Group on Mechanisms of Action and Resistance to Antimicrobials (GEMARA) on behalf of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), Madrid, Spain

    1 shared publication
  • Cristina Arjona-Torres

    Instituto Maimonides de Investigacion Biomedica de Cordoba

    1 shared publication

Latest Publications

  • Open Access

    Evaluation of carbapenem inactivation method-based phenotypic assays for the detection of GES-type carbapenemases in Enterobacterales, Pseudomonas aeruginosa , and Acinetobacter baumannii

    by Samuel García-García, Jorge Rodríguez-Grande, María Siller-Ruíz, Cristina Arjona-Torres, Esther Viedma, María Díez-Aguilar, Marta Hernández-García, Javier Fernández-Domínguez, Emilia Cercenado, Fernando Lázaro-Perona, et al.

    Detection of GES-type carbapenemases remains challenging because of their low prevalence and frequently weak hydrolytic activity against carbapenems. Carbapenem inactivation method (CIM)-based assays are widely used as phenotypic screening tools for carbapenemase detection; however, their performance in large collections of GES producers has not been systematically evaluated. We assessed the performance of CIM, modified CIM (mCIM), and CIM-Tris in a diverse collection of GES-producing clinical isolates, including 110 Enterobacterales and 108 Pseudomonas aeruginosa, recovered from Spanish hospitals (2010–2024), and 10 Acinetobacter baumannii isolates, mostly obtained from a hospital in Egypt. Whole-genome sequencing was carried out for species confirmation and resistome analysis. Meropenem MICs were determined by broth microdilution. Overall, 92.1% of isolates were GES-carbapenemase producers (CP), whereas 7.9% expressed GES-type extended-spectrum β-lactamases (ESBLs). In Enterobacterales (predominantly carrying bla GES-6 ), mCIM improved sensitivity compared with CIM (63.6% vs 40.0%), although many isolates remained undetected due to low meropenem MICs (MIC 50 , 0.5 µg/mL). In CP- P. aeruginosa (mainly bla GES-5 ), CIM, mCIM, and CIM-Tris showed sensitivities of 89.1%, 94.6%, and 100%, respectively; however, CIM-Tris yielded false-positive results in 50% of non-CP isolates (mostly bla GES-1 producers). Meropenem MICs in P. aeruginosa were higher (MIC 50 , >32 µg/mL). In A. baumannii , CIM-Tris improved sensitivity compared with CIM (100% vs 25.0%). These findings indicate that CIM-based methods can detect GES-type carbapenemases, but performance varies according to bacterial species and GES variant, and reduced specificity may occur in isolates producing GES-type ESBLs. Complementary molecular testing may therefore be necessary to ensure accurate detection of GES-type carbapenemases in routine clinical laboratories. IMPORTANCE: GES-type carbapenemases represent an important but underrecognized diagnostic challenge due to their low global prevalence, heterogeneous hydrolytic activity, and the limited performance data available for routine phenotypic detection methods. Although CIM-based assays are widely implemented in clinical microbiology laboratories for carbapenemase screening, their performance against GES-producing organisms has not been comprehensively evaluated across different bacterial genera and GES variants. In this study, we evaluated the performance of CIM, modified CIM (mCIM), and CIM-Tris in a large multicenter collection of well-characterized GES-producing clinical isolates, including Enterobacterales, Pseudomonas aeruginosa , and Acinetobacter baumannii . Our findings demonstrate substantial variability in assay performance according to bacterial species and GES variant. Notably, mCIM improved sensitivity among Enterobacterales with low meropenem MICs, whereas CIM-Tris achieved excellent sensitivity in P. aeruginosa and A. baumannii but at the expense of reduced specificity in isolates producing GES-type ESBLs. To the best of our knowledge, this is the first study directly comparing multiple CIM-based approaches in such a large and taxonomically diverse collection of GES-producing isolates.


  • An accurate amplification-free CRISPR/Cas12a-based assay for GES β-lactamase detection

    by Daniel Pablo-Marcos, Leticia Fernández-Diego, Jorge Rodríguez-Grande, Nuria Fraile-Valcárcel, Concha Ortiz-Cartagena, Olga Pacios, Samuel García-García, Sergio García-Fernández, Lucía Blasco, Alain Ocampo-Sosa, et al.